
Last year, Sanofi received authorization to market Dupixent as a treatment for childhood eczema to patients aged 6 and 11. Now, it seems that the company is setting its sights on even younger children.
In this vein, the firm recently published results from a new phase III study of the drug, where it was tested on young children aged 6 months to 5 years with moderate to severe eczema, also known as atopic dermatitis.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app